4.5 Article

A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats

期刊

VACCINE
卷 26, 期 31, 页码 3842-3852

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.05.016

关键词

henipavirus; subunit vaccine; CpG; mucosal immunity

资金

  1. NIAID NIH HHS [AI057168, U01 AI077995, U54 AI057168] Funding Source: Medline

向作者/读者索取更多资源

Nipah virus (NiV) and Hendra virus (HeV) are closely related deadly zoonotic paramyxoviruses that have emerged and re-emerged over the last 10 years. In this study, a subunit vaccine formulation containing only recombinant, soluble, attachment glycoprotein from HeV (sG(HeV)) and CpG adjuvant was evaluated as a potential NiV vaccine in the cat model. Different amounts of sG(HeV) were employed and sG-induced immunity was examined. Vaccinated animals demonstrated varying levels of NiV-specific Ig systemically and importantly, all vaccinated cats possessed antigen-specific IgA on the mucosa. Upon oronasal challenge with NiV (50,000 TCID50), all vaccinated animals were protected from disease although virus was detected on day 21 post-challenge in one animal. The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses. (C) 2008 CSIRO. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据